Research Article
GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF-κB Signaling Pathways
Figure 5
General histopathologic changes and radiological evaluation of GLX on CFA-induced TMJ inflammation in rats. (a) Schematic of the in vivo experiments. (b) Histopathologic changes in the rat TMJ after treatment on days 7 and 14 for each group. (c) Micro-CT scanning of rat TMJ after treatment on days 7 and 14 for each group. (d) Quantification of micro-CT scanning of rat TMJ after treatment on days 7 and 14 for each group ( independent animals). The data represent the from three independent replicates (one-way ANOVA with Tukey’s post hoc tests). , compared with the saline group; #, ## compared with the CFA group.
(a) |
(b) |
(c) |
(d) |